Topiramate in the treatment of trichotillomania: An open-label pilot study

International Clinical Psychopharmacology

Volumn 21, Issue 5, 2006, Pages 255-259

  Lochner, Christine ^a,c   Seedat, Soraya ^a   Niehaus, Dana J H ^a   Stein, Dan J ^a,b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NONE   (South Africa)

Author keywords

Open label; Topiramate; Treatment; Trichotillomania

Indexed keywords

TOPIRAMATE;

ADULT; ANALYSIS OF VARIANCE; ANOMIA; ANXIETY; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIPLOPIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; IMPULSE CONTROL DISORDER; INSOMNIA; LANGUAGE DISABILITY; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL HEALTH; MIGRAINE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; SLURRED SPEECH; SPEECH DISORDER; TREATMENT RESPONSE; TRICHOTILLOMANIA; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; CENTRAL NERVOUS SYSTEM AGENTS; FEMALE; FRUCTOSE; HUMANS; MALE; PILOT PROJECTS; TRICHOTILLOMANIA;

EID: 33746755981     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200609000-00002     Document Type: Article

References (38)

1. Adu L, Lessig M, Shapira N (2001). Topiramate in the treatment of trichotillomania. Southern Association for Research in Psychiatry 14th Annual Meeting, Gainesville, Florida.
2. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Ben Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U (2003). Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 11:556-562.
4. Benarroche CL (1990). Trichotillomania symptoms and fluoxetine response. New Research Program and Abstracts, 143rd meeting of the APA. New York, New York. NR327, p. 173.
5. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G (1999). A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 52:1330-1337.
6. Bouwer C, Stein DJ (1998). Trichobezoars in trichotillomania: case report and literature overview. Psychosom Med 60:658-660.
7. Christenson GA, Mackenzie TB, Mitchell JE, Callies AL (1991a). A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 148:1566-1571.
8. Christenson GA, Pyle RL, Mitchell JE (1991b). Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry 52:415-417.
9. Dannon PN (2003). Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 26:1-4.
10. Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M (2005). Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 28:6-10.
11. Diefenbach GJ, Tolin DF, Hannan S, Crocetto J, Worhunsky P (2005). Trichotillomania: impact on psychosocial functioning and quality of life. Behav Res Ther 43:869-884.
12. du Toit PL, van Kradenburg J, Niehaus D, Stein DJ (2001). Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview. Compr Psychiatry 42:291-300.
13. First MB, Spitzer RL, Gibbon M, Williams JBW (1998). Structured Clinical Interview for DSM-IV Axis I Disorders - patient edn (SCID-I/P, version 2.0, 8/98 Revision). New York, New York: Biometrics Research Department, New York State Psychiatric Institute.
14. Guy W (1976). ECDEU Assessment manual for psychopharmacology. US Department Health, Education and Welfare publication (ADM) 76-338. Washington D.C., Superintendent of Documents, US Government Printing Office, US Department of Health, Education, and Welfare.
15. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
16. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. (2003). Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677-1685.
17. Keuthen NJ, O'Sullivan RL, Ricciardi JN, Shera D, Savage CR, Borgmann AS, et al. (1995). The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. development and factor analyses. Psychother Psychosom 64:141-145.
18. Koran LM, Ringold A, Hewlett W (1992). Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull 28:145-149.
19. McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, et al. (2003). Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 160:255-261.
20. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
21. O'Sullivan RL, Keuthen NJ, Hayday CF, Ricciardi JN, Buttolph ML, Jenike MA, Baer L (1995). The Massachusetts General Hospital (MGH) Hairpulling Scale: 2. reliability and validity. Psychother Psychosom 64:146-148.
22. Reife R, Pledger G, Wu SC (2000). Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 41 (Suppl 41):S66-S71.
23. Rothbaum BO, Shaw L, Morris R, Ninan PT (1993). Prevalence of trichotillomania in a college freshman population. J Clin Psychiatry 54:72-73.
24. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F (2004). Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 37:37-40.
25. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G (1999). A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 52:1882-1887.
26. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, et al. (1994). Functional impairment in social phobia. J Clin Psychiatry 55:322-331.
27. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE (2000). An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41 (Suppl 1):S3-S9.
28. Shapira NA, Goldsmith TD, McElroy SL (2000). Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 61:368-372.
29. Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK (2002). Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol 5:141-145.
30. Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ (2004). Effects of topiramate in adults with Prader-Willi syndrome. Am J Ment Retard 109:301-309.
31. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L (2003). Topiramate in the treatment of chronic migraine. Cephalalgia 23:820-824.
32. Stanley MA, Bowers TC, Swann AC (1990). Trichotillomania and obsessive-compulsive disorder. New Research Program and Abstracts of the 143rd meeting of the APA. New York, New York. NR292. pp. 158.
33. Stewart RS, Nejtek VA (2003). An open-label, flexible dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 64:49-52.
34. Swedo SE (1993). Trichotillomania. In: Hollander E, editor. The obsessive-compulsive related disorders. Washington DC: American Psychiatric Press, Inc.; pp. 93-111.
35. Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J (2002). Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J Clin Psychiatry 63:981-984.
36. Van Ameringen M, Mancini C, Pipe B, Bennett M (2004). Topiramate augmentation in a case series of treatment resistant obsessive-compulsive disorder. Presented at the XXIVth Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Paris, France.
37. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH (1997). Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28:167-179.
38. Winchel RM, Jones JS, Stanley B, Molcho A, Stanley M (1992). Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry 53:304-308.